Serostim® is the only recombinant human growth hormone approved by the FDA for the treatment of HIV-associated wasting or cachexia in patients receiving antiretrovial therapy. It has been shown to significantly increase lean body mass and body weight and improve physical endurance.
Innovative Delivery Systems
Serostim® is administered by subcutaneous needle injection or by a needle-free delivery device that eliminates the risk of needle-stick injury.
Indication
Serostim® [somatropin [rDnA origin) for injection] is indicated for the treatment of HIV-associated wasting or cachexia to increase lean body mass and body weight, and improve physical endurance. Concomitant antiretroviral therapy is necessary.
Important Safety Information
Growth hormone therapy should not be initiated in patients with acute critical illness due to complications following open heart or abdominal surgery, multiple accidental trauma or acute respiratory failure. Serostim should not be used in patients with active cancer or in patients hospitalized in intensive care. Patients with a history of diabetes or related glucose intolerance problems should be monitored closely during Serostim treatment. Common side effects with Serostim include joint pain and swelling. these side effects can usually be managed with treatment or a change in Serostim dose. See
full prescribing information for complete disclosure.
This information is not intended to replace discussion with your doctor.
![Serostim® [somatropin (rDNA origin) for injection]](/cmg.emdserono_us/en/images/Serostim_Teresa_tcm115_61664_new_tcm115_62105.jpg "Serostim® [somatropin (rDNA origin) for injection]")
